LantheusLNTH
LNTH
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
48% more call options, than puts
Call options by funds: $55M | Put options by funds: $37.3M
11% more repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 167
6.04% more ownership
Funds ownership: 101.58% [Q3] → 107.62% (+6.04%) [Q4]
7% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 75
3% less funds holding
Funds holding: 493 [Q3] → 476 (-17) [Q4]
13% less capital invested
Capital invested by funds: $7.72B [Q3] → $6.69B (-$1.02B) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 8 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$112
16%
upside
Avg. target
$120
25%
upside
High target
$127
32%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Justin Walsh 25% 1-year accuracy 3 / 12 met price target | 27%upside $122 | Buy Maintained | 21 Mar 2025 |
Truist Securities Richard Newitter 53% 1-year accuracy 23 / 43 met price target | 32%upside $127 | Buy Maintained | 27 Feb 2025 |
JMP Securities David Turkaly 31% 1-year accuracy 8 / 26 met price target | 16%upside $112 | Market Outperform Reiterated | 14 Jan 2025 |
Financial journalist opinion
Positive
Seeking Alpha
3 weeks ago
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics. Pylarify's potential patent expiration in 2026 poses a risk, but management is actively seeking to extend protections and diversify revenue streams.
Neutral
The Motley Fool
1 month ago
Lantheus' Pylarify Hit $1B in 2024 Sales
Lantheus Holdings (LNTH -1.07%) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions.
Neutral
Seeking Alpha
1 month ago
Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q4 2024 - Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Amanda Morgan - Chief Commercial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities Paul Choi - Goldman Sachs Matt Taylor - Jefferies Yuan Zhi - B. Riley Larry Solow - CJS Securities Justin Walsh - Jones Trading Andy Hsieh - William Blair John Vandermosten - Zacks Kemp Dolliver - Brookline Capital Markets David Turkaly - Citizens JMP Operator Good morning.
Positive
The Motley Fool
1 month ago
Lantheus (LNTH): A 10x Opportunity in Radiopharmaceuticals
Explore the exciting world of Lantheus Holdings (LNTH 1.39%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
GlobeNewsWire
1 month ago
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D.
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus' strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent.
Negative
The Motley Fool
1 month ago
Why Lantheus Holdings Stock Got Thrashed on Tuesday
Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day.
Neutral
PRNewsWire
2 months ago
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent , PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January 28, 2025, at 8:30 AM ET BEDFORD, Mass. , Jan. 28, 2025 /PRNewswire/ -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen"), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Neutral
GlobeNewsWire
2 months ago
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities
Neutral
GlobeNewsWire
2 months ago
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market
Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease
Positive
Seeking Alpha
2 months ago
Lantheus Holdings: Powerhouse Potential In 2025
Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, is projected to reach $2.5 billion by 2030, driven by its superior PSMA PET imaging technology. DEFINITY holds an 80% market share in ultrasound imaging, with the market expected to nearly double, further solidifying Lantheus' financial stability.
Charts implemented using Lightweight Charts™